Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
37.02
+0.91 (2.52%)
At close: Jun 10, 2026, 4:00 PM EDT
37.00
-0.02 (-0.05%)
After-hours: Jun 10, 2026, 4:04 PM EDT

Enliven Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
2,2559151,101571430237
Market Cap Growth
180.18%-16.86%92.67%32.88%81.78%-84.71%
Enterprise Value
1,754452.76787.63318.33504.27146.71
Last Close Price
37.0215.4022.5013.8416.369.00
PB Ratio
4.851.993.552.32-5.602.75
P/TBV Ratio
4.881.903.422.00-0.660.36
Debt / Equity Ratio
-00000.00
Net Debt / Equity Ratio
-1.00-1.01-1.01-1.030.98-1.04
Net Debt / EBITDA Ratio
3.923.873.022.881.961.75
Net Debt / FCF Ratio
6.906.574.284.122.311.92
Quick Ratio
39.3827.9219.699.787.7812.52
Current Ratio
40.3228.6619.9910.288.0012.86
Return on Equity (ROE)
-21.64%-26.95%-32.04%-44.90%-47.39%-60.29%
Return on Assets (ROA)
-24.60%-29.84%-35.08%-47.04%-43.85%-55.77%
Return on Invested Capital (ROIC)
-7702.69%-2682.01%-897.91%-785.75%-1150.90%-6300.31%
Return on Capital Employed (ROCE)
-25.37%-31.10%-37.62%-52.28%-48.48%-60.16%
Buyback Yield / Dilution
-21.96%-20.38%-32.43%-1037.74%10.25%0.00%
Total Shareholder Return
-21.96%-20.38%-32.43%-1037.74%10.25%0.00%
SEC Filings: 10-K · 10-Q